LRN Stock Analysis: Stride | NYSE
Education & Training Services | NYSE, USA | Market Cap: 3.334m USD | 12M Return: -47.4% | US86333M1080 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 87.8M
EPS Trend: 98.4%
Qual. Beats: 1
Rev. Trend: 98.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Stride, Inc. (NYSE: LRN) is a U.S.-based provider of online curriculum, software platforms, and educational services serving K-12 and adult learners across public schools, school districts, charter boards, private schools, consumers, employers, and government agencies. The company offers an integrated package of products and professional support for virtual and blended public schools, learning software for traditional schools and districts, individual online courses in core subjects, and tuition-based private schools. It also operates career learning programs through its Galvanize, Tech Elevator, and MedCerts brands, delivering skills training in software engineering, healthcare, and medical fields to adult learners, along with staffing and talent development services for employers.
Formerly known as K12 Inc., the company rebranded as Stride, Inc. in December 2020 and is headquartered in Reston, Virginia. Stride operates within the Education Services sub-industry of the Consumer Discretionary sector, an area that has expanded with the broader adoption of digital and remote learning models and growing employer demand for workforce-focused, skills-based training.
- K-12 online enrollment growth drives core segment revenue
- Career learning expansion through MedCerts and Tech Elevator acquisitions
- State regulation and funding cuts threaten online charter enrollment
| Net Income: 338.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA -1.68 > 1.0 |
| NWC/Revenue: 56.68% < 20% (prev 55.29%; Δ 1.39% < -1%) |
| CFO/TA 0.18 > 3% & CFO 433.8m > Net Income 338.2m |
| Net Debt (-284.0m) to EBITDA (579.5m): -0.49 < 3 |
| Current Ratio: 5.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.3m) vs 12m ago -4.89% < -2% |
| Gross Margin: 37.75% > 18% (prev 39.24%; Δ -1.49% > 0.5%) |
| Asset Turnover: 106.5% > 50% (prev 104.9%; Δ 1.63% > 0%) |
| Interest Coverage Ratio: 38.46 > 6 (EBIT TTM 452.9m / Interest Expense TTM 11.8m) |
| A: 0.59 (Total Current Assets 1.72b - Total Current Liabilities 288.9m) / Total Assets 2.44b |
| B: 0.49 (Retained Earnings 1.18b / Total Assets 2.44b) |
| C: 0.19 (EBIT TTM 452.9m / Avg Total Assets 2.36b) |
| D: 2.03 (Book Value of Equity 1.63b / Total Liabilities 803.2m) |
| Altman-Z'' = 8.85 = AAA |
| DSRI: 1.13 (Receivables 664.8m/559.6m, Revenue 2.52b/2.41b) |
| GMI: 1.04 (GM 39.24% / 37.75%) |
| AQI: 1.03 (AQ_t 0.25 / AQ_t-1 0.25) |
| SGI: 1.05 (Revenue 2.52b / 2.41b) |
| TATA: -0.04 (NI 338.2m - CFO 433.8m) / TA 2.44b) |
| Beneish M = -2.83 (Cap -4..+1) = A |
As of August 12, 2026, the stock is trading at USD 79.09 with a total of 1,184,874 shares traded. Over the past week, the price has changed by -1.69%, over one month by -14.05%, over three months by -9.45% and over the past year by -47.42%.
Current recommended Stop Loss: 74.40 (which is 5.9% or 1.1 ATR below the current price).
Stride has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy LRN.
- StrongBuy: 2
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 109 | 37.8% |
P/E Trailing = 11.5605
P/E Forward = 9.6432
P/S = 1.3242
P/B = 2.1007
P/EG = 0.482
Revenue TTM = 2.52b USD
EBIT TTM = 452.9m USD
EBITDA TTM = 579.5m USD
Long Term Debt = 418.0m USD (from longTermDebt, last quarter)
Short Term Debt = 63.2m USD (from shortTermDebt, last quarter)
Debt = 674.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 128.0m
Net Debt = -284.0m USD (calculated: Debt 674.0m - CCE 958.0m)
Enterprise Value = 3.05b USD (3.33b + Debt 674.0m - CCE 958.0m)
Interest Coverage Ratio = 38.46 (Ebit TTM 452.9m / Interest Expense TTM 11.8m)
EV/FCF = 8.59x (Enterprise Value 3.05b / FCF TTM 355.0m)
FCF Yield = 11.64% (FCF TTM 355.0m / Enterprise Value 3.05b)
FCF Margin = 14.10% (FCF TTM 355.0m / Revenue TTM 2.52b)
Net Margin = 13.43% (Net Income TTM 338.2m / Revenue TTM 2.52b)
Gross Margin = 37.75% ((Revenue TTM 2.52b - Cost of Revenue TTM 1.57b) / Revenue TTM)
Gross Margin QoQ = 34.16% (prev 36.76%)
Tobins Q-Ratio = 1.25 (Enterprise Value 3.05b / Total Assets 2.44b)
Interest Expense / Debt = 1.75% (Interest Expense 11.8m / Debt 674.0m)
Taxrate = 23.34% (103.0m / 441.2m)
NOPAT = 347.2m (EBIT 452.9m * (1 - 23.34%))
Current Ratio = 5.94 (Total Current Assets 1.72b / Total Current Liabilities 288.9m)
Debt / Equity = 0.41 (Debt 674.0m / totalStockholderEquity, last quarter 1.63b)
Debt / EBITDA = -0.49 (Net Debt -284.0m / EBITDA 579.5m)
Debt / FCF = -0.80 (Net Debt -284.0m / FCF TTM 355.0m)
Total Stockholder Equity = 1.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.30% (Net Income 338.2m / Total Assets 2.44b)
RoE = 21.31% (Net Income TTM 338.2m / Total Stockholder Equity 1.59b)
RoCE = 22.59% (EBIT 452.9m / Capital Employed (Equity 1.59b + L.T.Debt 418.0m))
RoIC = 16.66% (NOPAT 347.2m / Invested Capital 2.08b)
WACC = 2.67% (E(3.33b)/V(4.01b) * Re(2.94%) + D(674.0m)/V(4.01b) * Rd(1.75%) * (1-Tc(0.23)))
Discount Rate = 2.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 3.72%
Shares (quarterly) Correlation: 62.45 | Cagr: 3.66%
[DCF] Terminal Value 74.77% ; FCFF base≈362.1m ; Y1≈349.0m ; Y5≈340.7m
[DCF] Fair Price = 135.5 (EV 5.35b - Net Debt -284.0m = Equity 5.63b / Shares 41.6m; r=8.35% [WACC [floored]]; 5y FCF grow -4.78% → 2.50% )
EPS Correlation: 98.39 | EPS CAGR: 40.94% | SUE: 0.92 | # QB: 1
Revenue Correlation: 98.30 | Revenue CAGR: 12.80% | SUE: 0.56 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.30 | Chg30d=-13.55% | Revisions=+25% | Analysts=3
EPS next Quarter (2026-12-31): EPS=2.67 | Chg30d=+8.10% | Revisions=-25% | Analysts=3
EPS current Year (2027-06-30): EPS=8.73 | Chg30d=-0.34% | Revisions=-40% | GrowthEPS=+4.8% | GrowthRev=+2.0%
EPS next Year (2028-06-30): EPS=9.28 | Chg30d=-1.63% | Revisions=+25% | GrowthEPS=+6.3% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: -12% (up=2, down=3)